Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Wins $338K from US Air Force to Develop Arrays to Detect Pathogens

NEW YORK, Sept. 28 (GenomeWeb News) - CombiMatrix has won a one-year, $338,000 contract from the US Air Force to develop and produce microarrays that detect pathogens, its parent company, Acacia Research, said today.

 

Under the agreement, CombiMatrix will develop microarrays to detect pathogens that cause upper respiratory infections and that infect wounds. The first array will identify upper respiratory infections that can cause pneumonia, bird flu, and SARS. The Air Force Institute of Occupational Health has committed to purchasing the arrays for evaluation and use. CombiMatrix will be able to make them commercially available to other users as well.

 

The contract results from a prior collaboration with the AFIOH that led to the development of a microarray to identify different serotypes of influenza A.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.